QTTB   $3.25  -7.93% Market Open

Q32 Bio Inc

Current temperature: 3.93
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 5
Target Price Mean 17
Mean unverified/preliminary 17 / 17
Target Price Low / High 9 / 22
Median / STD DEV 20 / 5.18
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy Buy Buy
rsi Buy ActivelyBuy ActivelyBuy
macd Sell None None
stoch Sell None None
ma20 None Sell None
ma50 Sell None None
ma100 Buy Buy Buy
Candlestick PatternDec. 19, 2024 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US7469641051
ceo Ms. Jodie Pope Morrison
Website https://www.q32bio.com
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.